What Dazit Treats: Main Uses and Benefits

Dazit is commonly used across domains where additional symptomatic support is needed, focusing on conditions presenting with inflammatory or irritative states. This medication is used for easing symptoms related to allergic rhinitis (seasonal and perennial) and chronic urticaria (hives).

---

Symptom Relief and Patient Benefit

The medication is applied in clinical settings that involve episodic or fluctuating manifestations, such as sneezing, a runny nose, congestion, and itchy, watery eyes associated with rhinitis. It also helps address symptom clusters that create noticeable functional strain, primarily the intense generalized pruritus (itching) and the presence of wheals in chronic hives.

It provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load during periods of heightened symptoms. This profile is designed for patients seeking symptomatic relief that is not associated with drowsiness.

Quick Fact: Relief for Pruritus
Dazit provides support that helps ease the overall symptom burden, particularly by managing the intense itching associated with chronic hives.

Regulatory References

1. NIH MedlinePlus overview

Eligibility for Dazit (Desloratadine) — Official Regulatory Information

Contraindicated Populations (Must Not Use)

The primary absolute exclusion for Dazit is a documented hypersensitivity or allergy to the active substance, desloratadine, its parent compound, loratadine, or any of the other ingredients (excipients) in the specific formulation. Individuals with known allergies to these components must not take this medicine.

Restricted and Cautionary Use

Population/Condition	Eligibility Status (Regulatory)
Age Restriction (Tablets)	Not recommended for children below 12 years of age (safety and efficacy not established).
Infants (Oral Solution)	Use not established or not recommended for children under 6 months (or under 2 years for some labels).
Pregnancy	Not recommended as a precautionary measure, despite large human data sets showing no adverse effects.
Breastfeeding	Not recommended as the substance passes into breast milk, and the effect on the nursing infant is unknown.
Severe Renal/Hepatic Impairment	Use with caution; a starting dose adjustment (e.g., every other day) is generally recommended for adults.
History of Seizures	Use with caution in patients with a medical or family history of seizures, especially young children.
Metabolic/Genetic Disorders	Patients with rare hereditary conditions such as galactose intolerance or Lapp lactase deficiency must avoid tablets containing specific excipients like lactose, when applicable.

Dazit (desloratadine) can interact with other medicines, which may increase the concentration of Dazit in the bloodstream or enhance the risk of side effects. It is important to inform your healthcare provider of all prescription, over-the-counter (OTC) medicines, and herbal supplements you are currently taking.

Drug-Drug Interactions

Increased plasma concentrations of Dazit have been observed when co-administered with certain medications. While these increases have generally not resulted in clinically significant changes to Dazit's safety profile, caution is advised. Consult your doctor if you are taking any of the following:

Drug Class	Examples of Interacting Medicines
Antifungals	Ketoconazole, Fluconazole
Macrolide Antibiotics	Erythromycin, Azithromycin, Clarithromycin
Gastrointestinal Drugs	Cimetidine
Antidepressants	Fluoxetine
HIV Protease Inhibitors	Ritonavir

Drug-Alcohol and Drug-Food Interactions

• Alcohol: Although Dazit is classified as a non-sedating antihistamine, drinking alcohol while taking this medicine may increase the risk of drowsiness, dizziness, or impaired coordination. It is best to avoid alcohol consumption.
• Food/Grapefruit: There are no known significant interactions between Dazit and food. However, consuming grapefruit or grapefruit juice may increase the levels of Dazit in your body and potentially raise the risk of side effects.

How Dazit Works: Mechanism of Action

The core mechanism of Dazit (Desloratadine) involves the molecule's selective, high-affinity binding to peripheral Histamine H1 receptors ( H1 Receptor), where it acts as a competitive antagonist. This molecular interaction interrupts the signal transduction cascade typically initiated by endogenous histamine, thereby modulating the activity within the vascular and sensory pathways.

Beyond this primary receptor blockade, the drug modifies the Inflammatory Mediator Systems by suppressing the release of various other pro-inflammatory chemicals, such as IL-6 and IL-8, from immune cells like mast cells. This action modifies the molecular steps that mediate inflammatory signaling amplification.

Due to its chemical structure, Dazit demonstrates peripheral selectivity, meaning its action is primarily limited to receptors outside the central nervous system (, CNS), focusing its effect on the microvasculature. This targeted mechanism stabilizes blood vessels, limiting histamine-induced increases in capillary permeability. This action results in a reduction of fluid movement from the vasculature into surrounding tissue, a key physiological consequence of the mechanism.

Administration Protocol

The use of Dazit is standardized for oral administration across all available forms, including the film-coated tablet, oral solution, and orally disintegrating tablet (ODT). The medicine is taken once daily and may be administered without regard to meals (with or without food).

---

Standard and Adjusted Dosing

The typical regimen for adults and adolescents 12 years of age and older is 5 mg once daily. Pediatric dosing, which utilizes the oral solution or ODT, is adjusted according to the child's age group:

• Children 6 to 11 years: 2.5 mg once daily.
• Children 12 months to 5 years: 1.25 mg once daily.
• Infants 6 to 11 months: 1 mg once daily.

For adult patients with either renal or hepatic impairment, the labeled starting regimen is modified to 5 mg every other day to account for the slower removal of the active ingredient from the body.

---

Procedural Conditions

To ensure proper intake, the oral solution must be measured with a calibrated device, not a standard household spoon. If using the ODT form, the tablet must be handled with dry hands and placed immediately on the tongue to dissolve, without being pushed through the foil blister pack. If a scheduled dose is missed, the standard protocol is to take it as soon as remembered; however, if it is nearly time for the next dose, the missed dose is typically skipped to avoid taking a double dose. The overall treatment duration is flexible, often guided by whether the condition is considered intermittent or persistent.

Research Evidence / Overview of Studies for Dazit

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research exploring Dazit in the context of allergic rhinitis has primarily relied on short-term, randomized, double-blind, placebo-controlled trials. These studies were structured to compare the activity of the agent against an inactive substitute (placebo). These trials were typically used in research examining symptom intensity or variability in populations of adults, adolescents, and children. The main outcomes measured in these studies focused on physical discomfort, such as sneezing, nasal congestion, and issues with itchy or watery eyes.

The studies monitored how symptoms evolved in the observed populations, with findings describing patterns observed when comparing the active treatment to the placebo. These observations were often seen within 24 hours of the first dose. While findings describe patterns observed in the studies, the evidence remains limited for long-term outcomes and the durability of observed responses beyond typical short-term study periods of four to six weeks.

Evidence for Use in Chronic Urticaria (Hives)

For conditions associated with acute or disruptive episodes like chronic urticaria, or hives, research examined the activity of Dazit in intermediate-term, randomized, placebo-controlled trials. The primary goal being the measurement of symptom scores for key dermal manifestations, such as the severity of itching (pruritus) and the number or size of wheals (hives).

Trials reported symptom scores and counts and compared those measurements to the patterns observed in the placebo group. The majority of evidence for this compound is derived from research exploring short-term symptom scores, meaning there is limited information for long-term outcomes. Comparative evidence is lacking, meaning there are limited head-to-head studies that directly compare Dazit against all other individual second-generation antihistamines.

Key Studies & References

1. Clinical Efficacy of Desloratadine in Chronic Urticaria

Common questions about Dazit (FAQ)

Q: Does taking Dazit require any special lifestyle changes, such as avoiding alcohol?

Official information advises caution regarding alcohol consumption while taking Dazit. Combining Dazit with alcohol may increase the risk of side effects such as drowsiness or dizziness.

Q: How does Dazit affect a person's ability to drive or operate machinery, according to safety data?

Based on clinical trials, Dazit has been shown to have no or negligible influence on the ability to drive or use machines. However, because individual responses can vary, official guidance suggests that individuals establish their own response before engaging in activities requiring full mental alertness.

Q: What are the known potential interactions between Dazit and antifungal medications?

Co-administration with certain antifungal medicines, such as Ketoconazole, has been shown in studies to result in increased levels of Dazit in the bloodstream.

Q: What is the mechanism of action of Dazit beyond just blocking histamine receptors?

Dazit's primary action is blocking the effects of histamine in the body. Beyond this, official documents describe that Dazit also modifies the inflammatory mediator systems by suppressing the release of certain pro-inflammatory chemicals like IL-6 and IL-8 from immune cells.

Q: What is the official information on Dazit's clearance from the body (pharmacokinetics theme)?

Dazit is extensively metabolized (broken down) in the body into an active compound. Official information indicates the drug has a long terminal half-life of approximately 21 to 27 hours, and it is eliminated from the body via both urine and faeces.

Q: Does Dazit interact with medicines commonly used for heart conditions or blood pressure?

Clinical studies have generally shown no statistically or clinically relevant cardiovascular effects—such as effects on heart rhythm—when Dazit is used alone at the recommended dosage.

Q: Is there a maximum length of time Dazit is officially recommended for continuous use?

Official documentation describes the length of use as being flexible and often guided by whether the condition is considered intermittent (short-term) or persistent (longer-term). There is no explicit maximum time limit set, but duration is determined by the nature of the condition being treated.

Q: Can Dazit be used to treat skin rashes and itching other than hives (urticaria)?

Official regulatory indications are limited to symptoms associated with allergic rhinitis and urticaria (hives), including itching and rash. The official indications do not explicitly list other specific types of rashes.

Q: What specific allergic conditions is Dazit officially indicated to treat?

According to official product information, Dazit is indicated for the relief of symptoms related to allergic rhinitis (including seasonal and perennial) and for the relief of the symptoms of chronic idiopathic urticaria (hives).

Q: What is the difference between Dazit and older antihistamines regarding drowsiness?

Dazit is classified as a second-generation antihistamine. Official sources describe this class as being non-sedating and having a low potential for drowsiness compared to older, first-generation antihistamines.

Q: How quickly does Dazit start to work after taking a dose?

Official pharmacokinetic data indicates that the active ingredient, desloratadine, can be detected in the bloodstream within 30 minutes of taking a dose. The maximum concentration in the body is typically reached after approximately 3 hours.

Q: What are the differences in how Dazit works compared to a nasal spray for allergies?

Dazit works systemically (throughout the body) by blocking H1 receptors to provide relief from both nasal and non-nasal allergy symptoms. This differs from most nasal sprays, which act locally only within the nasal passages.

Q: Does Dazit have a risk of interaction with common pain relievers or fever reducers?

Review of co-administration with a common pain reliever, such as ibuprofen (a type of non-steroidal anti-inflammatory drug or NSAID), has generally shown no significant interaction.

Q: Can Dazit cause changes in mood or unusual behavior, as described in official reports?

Official safety reports list hallucinations as a very rare or not known frequency adverse effect, and also include other nervous system disorders such as dizziness and somnolence.

Q: Is the tiredness (fatigue) side effect from Dazit generally considered mild or severe?

The side effect of fatigue is classified in official documents as a Common adverse reaction. This means it has been reported in 1% to 10% of individuals during clinical studies.

Q: Is the anti-itch effect of Dazit considered long-lasting based on clinical summaries?

Dazit is classified as a long-acting antihistamine. The drug's effects are reported to be sustained for up to 24 hours, which is the basis for its once-daily dosing regimen.

Q: Does the efficacy of Dazit change if it is taken at different times of the day?

Dazit is prescribed to be taken once daily. Official regulatory information does not specify an optimal time of day for administration to maximize efficacy.

Q: Are there specific warnings for using Dazit if one has a pre-existing neurological condition?

Regulatory caution is specifically advised for individuals with a personal or family history of seizures. This is because nervous system effects have been documented in official safety reports.

Q: Is Dazit a medicine that could affect the results of an allergy skin test?

As an H1 antihistamine, Dazit works by blocking the effects of histamine. Taking Dazit may suppress the necessary skin reaction, potentially interfering with the accurate results of an allergy skin test.

Q: What is the purpose of the 'M' in the name 'Dazit M' if that is a related product?

Related product names such as 'Dazit M' typically indicate a combination product. This means it contains Desloratadine along with a second active ingredient, which is commonly the Leukotriene receptor antagonist, Montelukast.

To maintain the effectiveness of Dazit (desloratadine), it must be stored correctly. Keep the medicine in its original container and carton, tightly closed, away from direct light and moisture. Store the tablets at or below 25°C (77°F), or at a controlled room temperature as specified in the product's instructions. Liquid formulations may have specific temperature requirements, often at or below 30°C. Crucially, ensure that Dazit is kept out of the sight and reach of children and pets.

Never use this medicine after the expiry date printed on the packaging. To dispose of unused or expired Dazit, do not flush it down the toilet or pour it into a drain, as this can harm the environment. The safest method is to return it to a pharmacy or utilize a local drug take-back program. Consult your pharmacist or local waste disposal service for guidance on local requirements for medication disposal.